Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Karyopharm Therapeutics (KPTI) Net Margin (2016 - 2025)

Historic Net Margin for Karyopharm Therapeutics (KPTI) over the last 14 years, with Q4 2025 value amounting to 299.89%.

  • Karyopharm Therapeutics' Net Margin fell 1988400.0% to 299.89% in Q4 2025 from the same period last year, while for Dec 2025 it was 134.21%, marking a year-over-year decrease of 815400.0%. This contributed to the annual value of 134.21% for FY2025, which is 815400.0% down from last year.
  • As of Q4 2025, Karyopharm Therapeutics' Net Margin stood at 299.89%, which was down 1988400.0% from 75.21% recorded in Q3 2025.
  • Karyopharm Therapeutics' Net Margin's 5-year high stood at 55.61% during Q2 2024, with a 5-year trough of 299.89% in Q4 2025.
  • For the 5-year period, Karyopharm Therapeutics' Net Margin averaged around 110.35%, with its median value being 99.36% (2022).
  • In the last 5 years, Karyopharm Therapeutics' Net Margin soared by 1599900bps in 2022 and then plummeted by -1988400bps in 2025.
  • Over the past 5 years, Karyopharm Therapeutics' Net Margin (Quarter) stood at 30.64% in 2021, then tumbled by -483bps to 117.42% in 2022, then fell by -6bps to 124.7% in 2023, then increased by 19bps to 101.04% in 2024, then tumbled by -197bps to 299.89% in 2025.
  • Its last three reported values are 299.89% in Q4 2025, 75.21% for Q3 2025, and 98.22% during Q2 2025.